The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Not yet recruiting
- Conditions
- Ovarian Neoplasms
- Interventions
- Genetic: homologous recombination deficiency
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06242392
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
Phase 2
Not yet recruiting
- Conditions
- Colo-rectal Cancer
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT06218888
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Early Phase 1
Not yet recruiting
- Conditions
- EGFR Positive Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06208033
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, China
MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy
Not yet recruiting
- Conditions
- MRIRadiotherapyPrognostic ModelCervical Cancer
- Interventions
- Radiation: Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06197126
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06197438
Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT06149767
Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06140589
- Locations
- 🇨🇳
No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province, Fuzhou, Fujian, China
Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Untreated Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06136910
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06136962
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer
Not yet recruiting
- Conditions
- Endometrial Neoplasms
- Interventions
- Diagnostic Test: next generation sequencing AND Immunohistochemical examination
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 350
- Registration Number
- NCT06126393
- Locations
- 🇨🇳
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath